Pediatric Clostridiodes difficile infection with toxic megacolon successfully treated with fecal microbiota transplantation Authors: Dana McCarney, Pamela Chen, Jenna Simes, Stacy A. Kahn Published: 2026 ABSTRACT AbstractThe rising incidence of pediatric Clostridioides difficile infection (CDI), particularly in medically complex patients, calls for novel, individualized treatments. While fecal microbiota transplantation (FMT) is well‐described for recurrent CDI, this report describes the first pediatric case of fulminant CDI with toxic megacolon successfully treated with FMT. This critically ill patient experienced failure of standard‐of‐care antibiotics and was a poor surgical candidate due to neutropenia and abdominal radiation for rhabdomyosarcoma. Ultimately, FMT rapidly resolved the patient's symptoms without adverse events. FMT should be considered for pediatric fulminant CDI. INTRODUCTION Pediatric Clostridiodes difficile infection (CDI) has a rising incidence, high recurrence rates, and high morbidity. 1 Fecal microbiota transplant (FMT), the transfer of stool from a healthy donor to a patient, is well‐studied in adults for both recurrent and severe/fulminant CDI treatment 2 ; however, experience in pediatrics is emerging. 3 The first pediatric FMT involved a 2‐year‐old with refractory CDI who received FMT via nasogastric (NG) tube in 2010. 4 In 2012, a 16‐month‐old with recurrent CDI received the first pediatric FMT via colonoscopy. 5 Though no randomized controlled trials for pediatric FMT exist, a multicenter retrospective cohort of 372 children with recurrent CDI reported 81% eradication rates after FMT. 6 Nevertheless, FMT efficacy and safety remain unknown in severe/fulminant pediatric CDI. We present a case of a 7‐year‐old patient with fulminant CDI with toxic megacolon, not a colectomy candidate due to neutropenia and abdominal radiation, who was treated with FMT enemas. CASE REPORT A 7‐year‐old girl with oculo‐facio‐cardio‐dental syndrome and metastatic rhabdomyosarcoma, undergoing chemotherapy and abdominal radiation, presented with febrile neutropenia (absolute neutrophil count [ANC] of 470) and mucoid diarrhea 7 days after receiving cycle 12 of vincristine, dactinomycin, and cyclophosphamide. Blood cultures and an extended respiratory viral panel were negative, and she was started on empiric intravenous (IV) vancomycin and cefepime. Standard CD glutamate dehydrogenase (GDH) antigen and toxin immunoassays were newly positive compared with 1 month prior. She developed clinical dehydration requiring hyperhydration from diarrhea; creatinine remained low due to pre‐existing malnutrition. She was transferred to the Intensive Care Unit (ICU) with abdominal distension leading to abdominal competition and respiratory distress requiring supplemental oxygen. Imaging confirmed toxic megacolon with transverse colonic diameter measuring 7.8 cm (Figure 1). She was started on vancomycin per NG tube and IV metronidazole; IV cefepime was continued for febrile neutropenia. Due to worsening abdominal distension (maximum girth: 72 cm), rectal vancomycin was added despite standard nil per rectum neutropenia precautions, and cefepime was broadened to meropenem. Her neutropenia and recent abdominal radiation made her a poor colectomy candidate. After discussion with colleagues in pediatric Intensive Care, Oncology, Infectious Diseases, Surgery, Gastroenterology, experts in FMT for fulminant CDI, and the patient's mother, we decided to pursue urgent FMT. Coronal slice of a CT abdomen and pelvis scan. Radiologic impression: “Diffuse mucosal enhancement of the mid to distal small bowel loops and of the colon with diffuse colonic wall thickening, and significant distension of the transverse colon that measures up to 7.8 cm in transverse diameter. No current sign of bowel perforation. These findings raise concern for toxic megacolon.” CT, computed tomography. FMT was delivered via retention enema. A 16 French Foley catheter was rectally inserted 10 cm, and 34 mL of thawed, previously frozen FMT from a stool bank (OpenBiome) was delivered via syringe and flushed with saline. The catheter remained in place with an inflated balloon for 15 min. The patient remained in left lateral decubitus position for another hour. Broad‐spectrum antibiotics were discontinued 24 h prior to promote FMT engraftment. Enteral vancomycin was held for 6 h peri‐FMT. Her trimethoprim‐sulfamethoxazole Pneumocystis jirovecii prophylaxis was changed to pentamidine. The patient received two FMT enemas 24 h apart and demonstrated dramatic improvement in clinical and laboratory markers, including abdominal girth reduction from 72 to 53 cm (Figure 2). Albumin decreased from 4.3 g/dL 1 week prior to hospitalization to a nadir of 2.1 g/dL on the day of FMT, with improvement to 3.4 g/dL at discharge. Her diet was advanced, and she was discharged on an enteral vancomycin taper that concluded 52 days after her first FMT. Timeline of hospital interventions (A), clinical trends (B), and laboratory value trends (C) before and after fecal microbiota transplant. The patient was re‐hospitalized for diarrhea and enteral intolerance 63 days after FMT. Repeat immunoassay showed negative CD toxin though GDH antigen remained positive. Ultimately, diarrhea was attributed to adenovirus infection and radiation colitis. She received a steroid pulse for radiation colitis and a 10‐day course of fidaxomicin. She has thrived in subsequent months with no hospitalizations or CDI recurrence. DISCUSSION This case highlights the successful treatment of pediatric fulminant CDI using FMT. The patient's critical status made timely access to FMT from a stool bank essential. The patient's recent chemotherapy likely impacted her course. Her oncologic history reduced interpretability of standard clinical and laboratory values followed in severe CDI (e.g., fever, white blood cell count, and creatinine). While chemotherapy‐associated neutropenic enterocolitis increases risk for and potentially exacerbates CDI, her subsequent ANC recovery reduced the risks of rectal therapies and antibiotic discontinuation and likely contributed to her clinical improvement. Reassuringly, FMT has been safely used even in critical neutropenia in an adult case of fulminant CDI. 7 Though we acknowledged bacterial translocation risk with rectal therapy, FMT delivery via retention enema was considered more likely to be effective than via NG tube given her ileus and safer than via sigmoidoscopy. We discontinued broad‐spectrum antibiotics 24 h prior to FMT to optimize engraftment, as suggested per literature review. 8 Enteral vancomycin was continued for synergistic anti‐CD effects. Additionally, though concurrent gastrointestinal infections were not excluded, FMT may still benefit non‐CDI intestinal dysbiosis in immunocompromised hosts and aid recovery. 9 Her readmission also highlights difficulties in distinguishing true opportunistic CDI recurrence from colonization. 10 Anti‐CD treatment was pursued out of caution given her recent fulminant course. Fidaxomicin was initiated rather than restarting vancomycin given her prior vancomycin exposure and fidaxomicin's selectivity and efficacy against CDI recurrence. CONCLUSION FMT is a promising alternative treatment for pediatric fulminant CDI, even with toxic megacolon. Cases should be selected with multidisciplinary oversight, recognizing our emerging understanding of microbiome manipulation. Future studies should explore the safety and efficacy of FMT in pediatric fulminant CDI. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. ETHICS STATEMENT Due to the patient being a minor, verbal consent was obtained from her mother prior to submission and publication.